D. E. Shaw & Co., Inc. Oncocyte Corp Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.76 - $15.98 $33,291 - $700,003	-43,805 Reduced 53.36%	38,291 $28,000
Q2 2022 Aug 15, 2022	SELL	$0.86 - $1.53 $140,828 - $250,543	-163,754 Reduced 66.61%	82,096 $74,000
Q1 2022 May 16, 2022	SELL	$1.15 - $2.25 $93,426 - $182,790	-81,240 Reduced 24.84%	245,850 $366,000
Q4 2021 Feb 14, 2022	BUY	$2.04 - $3.59 $249,824 - $439,642	122,463 Added 59.85%	327,090 $710,000
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $592,231 - $988,171	167,771 Added 455.21%	204,627 $729,000
Q2 2021 Aug 16, 2021	BUY	$3.77 - $6.0 $138,947 - $221,136	36,856 New	36,856 $212,000

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $260M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.